Overview

A Study of Vibegron in Pediatric Participants 2 Years to Less Than (<) 18 Years of Age With NDO and on CIC

Status:
Not yet recruiting

Trial end date:
2027-09-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety, efficacy, and PK of vibegron in pediatric participants with NDO who are regularly using CIC

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Urovant Sciences GmbH